Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency

Trial Profile

Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Albusomatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 02 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top